Maraviroc as GVHD Prophylaxis in Transplant Recipients

Graft Versus Host Disease (GVHD) Clinical Trial

Official title:
Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients

Status Terminated

Clinical Trial Summary

The purpose is to determine if the addition of Maraviroc to a standard transplant regimen will reduce the incidence of graft versus host disease in children and young adults after a stem cell transplant.

Clinical Trial Description

In the first stage, drug levels will be obtained to establish appropriate dosing. In the second stage of the study the investigators will study the effects of using Maraviroc in these patients. ;

Study Design

Related Conditions & MeSH terms

Diagnoses That Require Stem Cell Transplant
Graft Versus Host Disease (GVHD)
Graft vs Host Disease

Clinical Trial Details

NCT number	NCT02167451
Study type	Interventional
Source	Children's Hospital Medical Center, Cincinnati
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	July 2014
Completion date	September 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01463475` - University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol	N/A
Terminated	`NCT01324908` - Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis	N/A
Active, not recruiting	`NCT04167514` - Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)	Phase 3